期刊文献+

华法林个体化抗凝治疗的药学监护 被引量:9

下载PDF
导出
摘要 目的探讨临床药师在心房纤颤患者个体化抗凝治疗方案的制订与用药监护中的工作要点。方法临床药师通过参与查房,分析华法林抗凝治疗影响因素和制订个体化抗凝方案,以及安全用药知识宣教等。结果临床药师可参与确定符合患者特点的抗凝强度,积极开展有效合理的药学服务,避免不良反应的发生,提高患者长期抗凝治疗和国际标准化比值(INR)监测的依从性。结论在华法林个体化给药过程中,临床药师能够开展有特色的药学服务工作,提高药物治疗效果。
作者 向栋 韩勇
出处 《医药导报》 CAS 北大核心 2014年第5期682-683,共2页 Herald of Medicine
  • 相关文献

参考文献3

二级参考文献20

  • 1许俊堂.口服抗凝药的作用机制与临床应用(下)[J].中国医刊,2006,41(2):52-53. 被引量:8
  • 2杨扬,姚均迪,林晓耘.胺碘酮与华法林的相互作用[J].海军医学杂志,2006,27(3):269-271. 被引量:18
  • 3Torn M,Bollen W L,vander Meer FJ,etal.Risks of oral anticoagulant therapy with increasing age[J].Arch Intern Med,2005,165:1527.
  • 4Gage BF, Eby C, Milligan PE, et al. Use of pharmametice and clinical factors to predict the maintenance dose of warfarin[ J]. Thromb Haemost ,2004,91 ( 1 ) :871.
  • 5Fuster V, Ryden LE, Cannom DS,et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation ): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society [ J ]. Circulation, 2006,114 ( 7 ) : e257.
  • 6Chenhsu RY, Chiang SC, Chou MH, et al. Long-term treatmentwit warfarin in Chinese population [ J ]. Ann Pharmacother,2000,34(12) : 1395.
  • 7ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation[J].Circulation,2006, 114: 700-752.
  • 8HIRSHJ, FUSTER V, ANSELL J,et al.American heart association/American college of cardiology foundation guide to war-farin therapy[J]. Circulation, 2003,107:1692-1711.
  • 9HEIMARK L D, WIENKERS L, KUNZE K,et al.The mechanism of the interaction between amiodarone and warfarin in hu-mans [J]. Clin Pharrnacol Ther, 1992,51(4):398-407.
  • 10卫生部合理用药专家委员会.中国医师药师临床用药指南[M].第一版.重庆:重庆出版社,2009,4.

共引文献25

同被引文献117

  • 1赵洁,李超鹏,张之慧.心房颤动患者华法林抗凝治疗依从性调查分析[J].农垦医学,2014,36(1):68-71. 被引量:3
  • 2侯爱军,许俊堂,郭继鸿,王付龙,申玉良.华法林抗凝治疗中出血和血栓栓塞性不良反应及相关因素探讨[J].中国实用内科杂志:临床前沿版,2006,26(1):133-135. 被引量:15
  • 3YIN T, MIYATA T. Warfarin dose and the pharmacogen- omics of CYP2C9 and VKORCl-rationale and perspectives [J]. Thromb Res,2007,120( 1 ) :1-10.
  • 4LOEBSTEIN R, YONATH H, PELEG D, et al. Interindi- vidual variability in sensitivity to warfarin-Nature or nurture? [J]. Clin Pharm Ther,2001,70(2) :159-164.
  • 5CONSORTIUM I W P. Estimation of the warfarin dose with clinical and pharmacogenetic data [ J ]. New Engl J Med, 2009,360 ( 8 ) : 753.
  • 6WADELIUS M, PIRMOHAMED M. Pharmacogenetics of warfarin: current status and future challenges [ J ]. Pharmacogenomics J, 2007,7 ( 2 ) : 99-111.
  • 7CHA P C, MUSHIRODA T, TAKAHASHI A, et al. Genome- wide association study identifies genetic determinants of warfarin responsiveness for Japanese [ J ]. Hum Mol Genet, 2010,19(23) :4735-4744.
  • 8TAKEUCHI F,MCGINNIS R, BOURGEOIS S,et al. A geno- me-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose [ J ]. PLoS Genetics ,2009,5 ( 3 ) : e1000433.
  • 9BRECKENRIDGE A, ORME M, WESSELING H, et al. Pha- rmacokinetics and pharmacodynamics of the enantiomers of warfarin in man [J]. Clin Pharm Ther,1974,15 (4) :424- 430.
  • 10TAKAHASHI H, ECHIZEN H. Pharmacogenetics of warfarin elimination and its clinical implications [ J ]. Clin Pharm, 2001,40(8) :587-603.

引证文献9

二级引证文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部